Literature DB >> 3877356

Pharmacokinetic profiles of cyclosporine in rats. Influence of route of administration and dosage.

R Wassef, Z Cohen, B Langer.   

Abstract

This study was performed to determine the influence of different routes of administration and of variable doses of cyclosporine (CsA) on the pharmacokinetics of CsA in the rat. Seven groups of 4 adult female Lewis rats were given CsA once daily for 5 days: group 1: 5 mg/kg of CsA p.o. (by gavage); group 2: 10 mg/kg of CsA p.o.; Group 3: 5 mg/kg of CsA i.m.; group 4: 10 mg/kg of CsA i.m.; Group 5: 5 mg/kg of CsA s.c.; group 6: 10 mg/kg of CsA s.c., group 7: 10 mg/kg CsA i.p. CsA plasma levels were determined by RIA at 0, 2, 4, 6, 8, and 24 hr on days 1 and 4. Ease of administration was greatest in the s.c. groups (3 and 4), in which no anesthesia, no restraining device, and no special skills were required. Peak CsA levels varied greatly from group to group, as did trough levels and CsA bioavailability, as determined by the total area under the plasma CsA concentration-time curve. All groups exhibited great variation of CsA plasma level in the 24-hr period following administration, except group 3, in which the peak-to-trough difference was only 26.8% of peak level, as opposed to values over 60% in all other groups. We conclude that: (1) CsA may be administered to rats through different routes to achieve adequate plasma levels; (2) the route and dosage will greatly influence the pharmacokinetic profile of CsA; and (3) the SC route, in addition to being the easiest, provides reproducible and steady CsA plasma levels, with little variation over a 24-hr period.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877356     DOI: 10.1097/00007890-198511000-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats.

Authors:  S Koehn; F J Frey; R F Speck; T Zeugin; T Schaffner; A Zimmermann; B M Frey
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

2.  Species-specific cyclosporine metabolism.

Authors:  R Venkataramanan; C P Wang; K Habucky; R J Ptachcinski; G J Burckart; B Koneru; R Baker; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

3.  Cyclosporin A treatment and decreased fungal load/antigenemia in experimental murine paracoccidioidomycosis.

Authors:  T Y C Massuda; L A Nagashima; P C Leonello; M S Kaminami; M S Mantovani; A Sano; J Uno; E J Venancio; Z P Camargo; E N Itano
Journal:  Mycopathologia       Date:  2010-09-11       Impact factor: 2.574

4.  Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

Authors:  G Fricker; J Drewe; J Huwyler; H Gutmann; C Beglinger
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.

Authors:  T Matsunaga; M Shigetomi; T Hashimoto; H Suzuki; T Gondo; H Tanaka; T Sugiyama; T Taguchi
Journal:  Osteoporos Int       Date:  2007-05-10       Impact factor: 4.507

6.  Functional effects on glomerular hemodynamics of short-term chronic cyclosporine in male rats.

Authors:  S C Thomson; B J Tucker; F Gabbai; R C Blantz
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

7.  Cyclosporine is angiostatic.

Authors:  K Norrby
Journal:  Experientia       Date:  1992-12-01

Review 8.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

9.  Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4.

Authors:  P A Kelly; H Wang; K L Napoli; B D Kahan; H W Strobel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Oct-Dec       Impact factor: 2.569

10.  Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils.

Authors:  Diana Velluto; Damir Bojadzic; Teresa De Toni; Peter Buchwald; Alice A Tomei
Journal:  J Control Release       Date:  2020-10-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.